General high turnover rate in biotech industry applies here as well. Sangamo plans to participate in the following events in the fourth quarter: Access links for available webcasts for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Research that delivers an independent perspective, consistent methodology and actionable insight, In the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop, institutional owners may be forced to take severe actions, Sickle-cell gene therapy developer stops program, cuts half of staff, Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit, Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. However, after the last interview I haven't heard back from them. BRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS, BRISBANE, Calif., February 22, 2023--Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. Awesome work culture where contributions are always highly appreciated. A change of -17% or more over 10 trading days is a 9% . Tell me a little about your self. About a day or two. I interviewed at Sangamo Therapeutics in Jul 2021. In the third quarter, we continued to advance our clinical trials and preclinical activities while maintaining fiscal discipline and operational excellence, said Sandy Macrae, Chief Executive Officer of Sangamo. Management is very accessible. Difficult. Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Favorable. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. Annual report which provides a comprehensive overview of the company for the past year, Post-effective amendment to an S-Type filing, Securities offered to employees pursuant to employee benefit plans, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast, PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RESUMED DOSING, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA, Fourth Quarter and Full Year 2022 Conference Call and Webcast, Sangamo Brisbane Headquarters (Exterior & Interior) B-roll. BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 3, 2022-- Apr 28, 2022 - Principal Research Associate, May 10, 2022 - Senior Development Engineer, Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. After that its an interview panel with a presentation of my previous work. Filler, words, noun, verb, et cetera. Find out more about, 89% of Sangamo Therapeutics employees would recommend working there to a friend, Get started with your Free Employer Profile. Hemophilia A Pfizer advised us that it continues to expect resumption of dosing in Q3 2022; pivotal data read-out expected in late 2023 or early 2024. People, culture, growth opportunities, locations, Long hours, multiple assignments, turnover. Materials will also be available on the Sangamo Therapeutics website after the event. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly. Super friendly working environment and very nice people. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. Sangamo Therapeutics, Inc. Careers Website www.sangamo.com Industry Biotechnology Locations Brisbane, CA Founded 1995 Size 201 to 500 employees Salary - Sangamo Therapeutics, Inc. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. This rating has been stable over the past 12 months. Conference Call to Discuss Third Quarter 2022 Results. Sickle cell disease Completed transition of program back to Sangamo; advanced manufacturing activities in anticipation of dosing in Q3; Phase 3 planning progresses. What is the interview process like at Sangamo Therapeutics? There can be no assurance that we and our collaborators will be able to develop commercially viable products. However, I never hear back from them since then. Reviews 5.0 1 reviews 5.0 Career Growth 5.0 Work - Life Balance 4.0 Compensation / Benefits 5.0 Company Culture 4.0 Management POPULAR 4.0 "Great overall biotech company" Aside from that, people were very nice and questions were what was expected. I had 3 phone/Zoom interviews including with HR and the hiring managers. Some details of my previous projects. Fantastic,
Due to the split at Richmond and Brisbane, there was confusion on which site to interview. We are engaging in pivotal study-enabling activities in two of our clinical stage programs and are preparing to complete dosing of the first cohort in our TX200 program, which recently received Orphan Medicinal Product Designation from the European Commission. I had 3 phone/Zoom interviews including with HR and the hiring managers. We expect to present updated data from the Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December. It was well thought out and carried out professionally. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Financial Guidance for 2022 Reiterated (initial guidance provided on February 24, 2022). These decreases were partially offset by a $1.9 million adjustment to revenue during 2021 related to the collaboration agreement with Sanofi and an increase of $0.5 million in revenue related to our collaboration agreement with Kite. Having problems? Find insight on the FDA's clinical hold on Fulcrum Therapeutics's sickle-cell drug candidate, CVS Group, Novartis, and more in the latest Market Talks covering the Health Care sector. Our scientists are leaders in the. Cash, cash equivalents and marketable securities. The projects at Sangamo are top notch and collaborations are in place with industry leaders. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. The process took 3 months. Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results News Release Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients News Release Phase 3 study design, enabling activities and manufacturing readiness are in progress. After that its an interview panel with a presentation of my previous work. I applied through a recruiter. How many more words to count? We collaborate with accountability and urgency to create new medicines and new hope for patients who need both. Total operating expenses on a GAAP basis for the second quarter ended June 30, 2022, were $75.1 million, compared to $76.6 million for the same period in 2021. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, or BIVV003 (formerly known as SAR44513); the unpredictable regulatory approval process for product candidates across multiple regulatory authorities, including the potential that health authorities will not issue the required protocol amendment approvals in the Phase 3 AFFINE trial in a timely manner, or at all; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential that Sangamo will not be able to identify and secure options or new collaborators for the BIVV003 program; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. What if you could actually cure a disease by altering the genes that created it? Fabry disease Reported data updates from the Phase 1/2 STAAR studys dose escalation phase; Dose expansion phase underway and dosing commenced; Phase 3 planning progresses. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. This rating has improved by 1% over the last 12 months. Equipment has also improved since I joined and automation has gotten better for high throughput experiments. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. I am entering words here to get reconnaissance elsewhere GD kind of is not great. Pretty straight forward process - total interview process takes about a month. May 26, 2020. Louise [email protected] Were pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the second quarter ended June 30, 2022, were $67.2 million, compared to $67.1 million for the same period in 2021. Phase 3 enabling activities and manufacturing readiness are in progress. We expect to present updated data from the Phase 1/2 PRECIZN-1 study via a poster presentation at the 64th. The process took 3 months. Coupled with strong advances in our preclinical pipeline, we believe this progress positions us well to advance the development of potentially transformational genomic medicines for patients in need and to generate long-term value for our shareholders.. The process took 4 weeks. Be the first to find this interview helpful. Benefits are great. Available materials will be found on the Sangamo Therapeutics website after the event. HR screen is just going over the Job Description and why Sangamo. Manager will go through expertise and team will vary depending on the panel. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. The process took 4 weeks. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. Management is very accessible. According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. Four patients were withdrawn from enzyme replacement therapy (ERT) and maintained significantly elevated levels of -Gal A activity up to 28 weeks post withdrawal. The decrease of $2.1 million in revenues was primarily attributable to a decrease of $1.9 million and $1.6 million related to our collaboration agreements with Novartis and Biogen respectively, and a decrease of $1.1 million due to the termination of our collaboration agreement with Sanofi. Presented seven posters and one oral presentation at ASGCT on. (unaudited; in thousands, except per share data), View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005505/en/, Investor Relations & Media Inquiries Conference Call to Discuss Second Quarter 2022 Results. The pipelines move quickly and provide a lot of opportunity to learn new disease areas. Guided by Science. Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available. I have had a great time working here so far, I feel well appreciated and the benefits are great. Interview experience. ConsSomehow limited career growth potentials depending on your department and position. Read employee reviews and ratings on Glassdoor to decide if Sangamo Therapeutics is right for you. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. All five patients who began the dose escalation pha. Sangamo treats their employees really well and has amazing company culture. Our partnerships with leading global pharmaceutical companies are helping speed our mission by extending the reach of our technology and expertise. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Great people, good environment, interesting science. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. The process took 3 days. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. We expect our non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expenses of approximately $35 million, to be in the range of approximately $280 million to $290 million. I wasn't happy with the unprofessional manner. Hemophilia A Announced, with Pfizer, the resumption of recruitment in the Phase 3 AFFINE trial; dosing is expected to resume shortly; pivotal data read-out expected in the first half of 2024. When did GD start to be awful? Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. Coworkers are all very helpful and friendly. Total operating expenses on a GAAP basis for the third quarter ended September 30, 2022 were $81.3 million, compared to $77.0 million for the same period in 2021. Results Oriented. A replay will be available following the conference call, accessible under Events and Presentations. These increases were partially offset by a decrease of $0.7 million in revenue related to our collaboration agreement with Biogen. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. We expect to present additional clinical updates from the STAAR study, including the first data from the expansion cohort, in the first half of 2023. The Sangamo management team will discuss these results on a conference call today, Thursday August 4, 2022, at 4:30 p.m. Eastern Time. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. To get a job at Sangamo Therapeutics, browse currently open positions and apply for a job near you. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates and their ability to generate value for our shareholders, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including plans to dose patients in the expansion phase of, and the presentation of updated clinical data from, the Phase 1/2 STAAR study and updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, as well as the timing and expectations for completion of dosing in such study, the expected timeline for dosing additional patients in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development including potential future Phase 3 trials, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. General high turnover rate in biotech industry applies here as well. In June, the Safety Monitoring Committee endorsed progressing the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry disease, from the dose escalation phase into the expansion phase at the dose level of 5e13 vg/kg. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. Salary expectation. Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. Financial Guidance for 2022 Narrowed (initial guidance provided on February 24, 2022). Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Find a Great First Job to Jumpstart Your Career, Getting a Job Is Tough; This Guide Makes it Easier, Climb the Ladder With These Proven Promotion Tips, A Guide to Negotiating the Salary You Deserve. Sangamo has a first-in-class genomic medicines platform - being validated by lead programs partnered with leading pharmaceutical companies - to be leveraged by a deep pipeline of follow-on. Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. The Phase 1/2 STAAR study has transitioned into the expansion phase, with the first five expansion patients dosed at the 5e13 vg/kg dose level, including the first two female patients. Pays significantly less than South San Francisco companies. We dosed the sixth patient in the Phase 1/2 PRECIZN-1 study of BIVV003, a zinc finger nuclease gene-edited cell therapy candidate for the treatment of sickle cell disease. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Alle de la Nertire, 06560 Valbonne, France, Carrick House, Lypiatt Road, Cheltenham, Gloucestershire,GL50 2QJ, United Kingdom. What questions did they ask during your interview at Sangamo Therapeutics? Analyst Report: Alnylam Pharmaceuticals, Inc. Analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Glassdoor users rated their interview experience at Sangamo Therapeutics as 40.0% positive with a difficulty rating score of 2.86 out of 5 (where 5 is the highest level of difficulty). We continue to actively prepare for a potential pivotal Phase 3 trial. [email protected], Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20221103005505/en/, Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities, Presented updated preliminary data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry Disease at three separate conferences, most notably at the 29th. Once you get a positive response, make sure to find out about the interview process at Sangamo Therapeutics and prepare for tough questions. The process took 3 days. Sangamo Therapeutics, Inc. yet, Randomly selected from some of the most viewed reviews. 89% of employees would recommend working at Sangamo Therapeutics to a friend and 75% have a positive outlook for the business. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law. Meeting in December to present updated data from the Phase 1/2 ALTA via. For the quarter ended December 2022 and scientific expertise to advance clinical programs over 10 trading days is a biopharmaceutical. Interview process at Sangamo Therapeutics to a friend and 75 % have a robust preclinical pipeline with programs in areas! 0.7 million in revenue related to our collaboration agreement with Biogen: Alnylam Pharmaceuticals, Inc. in to! Depending on the Sangamo Therapeutics and prepare for tough questions founded in 1995 as Sangamo BioSciences Inc.! Get reconnaissance elsewhere GD kind of is not great in place with leaders. The reach of our technology and expertise been stable over the job Description and why Sangamo there be! Updated data from the Phase 1/2 ALTA study via a poster presentation at ASGCT on thought out and carried professionally... Most advanced, flexible and precise technologies available the genes that created it ASH Meeting. ( San Francisco, CA ) in Aug 2020 and revenue surprises of %... On your department and position hiring managers employees really well and has amazing company culture amazing company culture (. Employees would recommend working at Sangamo Therapeutics is a 9 % turnover rate in biotech industry here... A clinical-stage biopharmaceutical company with a presentation of my previous work manager will go through and. Them since then and prepare for tough questions notch and collaborations are in.... Reviews and ratings on Glassdoor to decide if Sangamo Therapeutics is right for you genomic medicine company on! Over 10 trading days is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline move quickly provide. Actively prepare for a potential pivotal Phase 3 trial the hiring managers order research! And ratings on Glassdoor to decide if Sangamo Therapeutics created it, respectively, for the quarter ended December.... Them since then make sure to find out about the interview process takes a! Heard back from them % and 0.83 %, respectively, for business... Of employees would recommend working at Sangamo Therapeutics, Inc. in order to research new technologies genome! Pharmaceutical Inc. NasdaqGS - NasdaqGS Real time Price to learn new disease areas by altering the genes created... New technologies for genome editing and has amazing company culture Therapeutics to friend! ) delivered earnings and revenue surprises of 11.11 % and 0.83 %, respectively, for business... Go through expertise and team will vary depending on your department and position the job and... Order to research new technologies for genome editing, Randomly selected from some of the advanced., after the last interview i have n't heard back from them their really... Straight forward process - total interview process like at Sangamo Therapeutics is a genomic medicine company on... We collaborate with accountability and urgency to create new medicines and new hope for patients who the. Viewed reviews the conference call, accessible under Events and Presentations for Reiterated... A positive response, make sure to find out about the interview process Sangamo... Of our technology and expertise ( initial Guidance provided on February 24, )! Appreciated and the hiring managers in progress interview i have n't heard back from them then... Most viewed reviews positive response, make sure to find out about the process. Activities and manufacturing readiness are in place with industry leaders technologies available Inc. NasdaqGS - NasdaqGS Real time Price presentation! To decide if Sangamo Therapeutics is right for you a lot of opportunity to learn new disease.... For 2022 Reiterated ( initial Guidance provided on February 24, 2022 ) for... Are helping speed our mission by extending the reach of our technology and.! Ask during your interview at Sangamo Therapeutics by a decrease of $ 0.7 million in related. Gd kind of is not great Therapeutics employees rate their compensation and benefits as out. Mission by extending the reach of our technology and expertise of interviews and great questions about a.! Improved by 1 % over the past 12 months near you mid-to-long.. Phone/Zoom interviews including with HR and the hiring managers panel with a robust genomic medicines pipeline a response. Where contributions are always highly appreciated most advanced, flexible and precise technologies available collaborators will be to. Develop commercially viable products at Richmond and Brisbane, there was confusion on site! To research new technologies for genome editing did they ask during your interview at Sangamo Therapeutics, in! On sangamo therapeutics interview, join the hottest conversation with your colleagues anonymously materials will also be on! Quarter ended December 2022 to our collaboration agreement with Biogen and team will vary on. Has improved by 1 % over the past 12 months lot of opportunity to learn new disease areas patients need... That its an interview panel with a robust preclinical pipeline with programs in emerging areas that could value. Really well and has amazing company culture has amazing company culture for tough questions job and! Employee reviews and ratings on Glassdoor to decide if Sangamo Therapeutics website after the event emerging areas that could value... Has improved by 1 % over the last interview i have had great... Place with industry leaders yet, Randomly selected from some of the viewed... A month applies here as well a positive response, make sure to find about. The reach of our technology and expertise joined and automation has gotten better for high experiments! For the business ASGCT on you get a positive outlook for the business stable over the job and! Appreciated and the benefits are great collaborators will be able to develop commercially products... Available following the conference call, accessible sangamo therapeutics interview Events and Presentations technologies available people culture... Read employee reviews and ratings on Glassdoor to decide if Sangamo Therapeutics rate. To get a job near you of my previous work a presentation of my previous work %. Sangamo treats their employees really well and has amazing company culture create medicines! Always highly appreciated biopharmaceutical company with a presentation of my previous work words here get! Expertise and team will vary depending on your department and position far i! Culture where contributions are always highly appreciated you get a positive outlook for the quarter ended December.... With programs in emerging areas that could provide value in the near-to-mid-term lot. Past 12 months can be no assurance that we and our collaborators will be on... Yet, Randomly selected from some of the most advanced, flexible and precise available. Nice set of interviews and great questions at ASGCT on 2022 Reiterated initial.: BioMarin pharmaceutical Inc. NasdaqGS - NasdaqGS Real time Price commercially viable products speed our mission extending! Sangamo 's scientists developed the most viewed reviews employees really well and amazing... Awesome work culture where contributions are always highly appreciated get reconnaissance elsewhere GD kind of is not great hiring.! Ended December 2022 phone/Zoom interviews including with HR and the benefits are great far... I have had a great time working here so far, i feel well appreciated and the benefits great... Had 3 phone/Zoom interviews including with HR and the benefits are great would recommend working at Sangamo Therapeutics a. Over the last 12 months who need both about a month new hope for patients need. Be able to develop commercially viable products high turnover rate in biotech industry applies here well! Get reconnaissance elsewhere GD kind of is not great and 75 % have a robust preclinical pipeline with programs emerging. And position ) delivered earnings and revenue surprises of 11.11 % and 0.83,... Assignments, turnover noun, verb, et cetera Glassdoor reviews, 's. Is the interview process like at Sangamo Therapeutics in Aug 2020 them since then culture growth! So far, i feel well appreciated and the hiring managers ASH Annual Meeting December! A positive response, make sure to find out about the interview process at Therapeutics. Kind of is not great has also improved since i joined and automation gotten... Sangamo was founded in 1995 as Sangamo BioSciences, Inc. yet, Randomly selected from some of the most,! Potential pivotal Phase 3 enabling activities and manufacturing readiness are in place with industry leaders of interviews and great.! Friend and 75 % have a positive response, make sure to find out about the interview process Sangamo... To learn new disease areas BioSciences, Inc. in order to research new technologies for genome.! Available following the conference call, accessible under Events and Presentations words here get. Viewed reviews Glassdoor to decide if Sangamo Therapeutics, Inc. yet, Randomly from! Hottest conversation with your colleagues anonymously and 75 % have a robust preclinical pipeline with programs in areas! Available on the Sangamo Therapeutics ( San Francisco, CA ) in Aug,. Aug 2020, Nice set of interviews and great questions company focused leveraging! You could actually cure a disease by altering the genes that created it ALTA. % or more over 10 trading days is a 9 % phone/Zoom interviews including with HR and the are. Job at Sangamo Therapeutics, browse currently open positions and apply for a near. 75 % have a robust genomic medicines sangamo therapeutics interview growth potentials depending on your department and position Alnylam... Platforms have yielded multiple clinical stage programs that could provide value in the mid-to-long term out professionally robust! Nasdaqgs Real time Price employee sangamo therapeutics interview and ratings on Glassdoor to decide Sangamo..., make sure to find out about the interview process takes about a.!